TY - JOUR
T1 - Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients
AU - Jongs, Niels
AU - Penninx, Brenda
AU - Arango, Celso
AU - Ayuso-Mateos, Jose Luis
AU - van der Wee, Nic
AU - Rossum, Inge Winter-van
AU - Saris, Ilja M J
AU - van Echteld, Amber
AU - Koops, Sanne
AU - Bilderbeck, Amy C
AU - Raslescu, Andreea
AU - Dawson, Gerard R
AU - Sommer, Bernd
AU - Marston, Hugh
AU - Vorstman, Jacob A
AU - Eijkemans, Marinus Jc
AU - Kas, Martien J
N1 - Funding Information:
The PRISM project ( www.prism-project.eu ) leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA . This publication reflects only the authors' views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.
Funding Information:
The PRISM project (www.prism-project.eu) leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This publication reflects only the authors' views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. Dr. Arango has also received funding support by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ?A way of making Europe?, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. Fundaci?n Familia Alonso and Fundaci?n Alicia Koplowitz.
Funding Information:
CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. BP has received (non-related) research funding from Jansen Research and Boehringer Ingelheim during the conduct of the study. MK has received (non-related) research funding from Novartis during the conduct of the study. BS was fully employed by Boehringer Ingelheim during the conduct of the study. HM was fully employed by Eli Lilly and Company during the conduct of the study. AR, ACB and GRD were fully employed by P1Vital during the conduct of the study. All other authors declare no conflict of interests.
Funding Information:
Dr. Arango has also received funding support by the Spanish Ministry of Science and Innovation . Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission , “A way of making Europe”, CIBERSAM . Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. Fundación Familia Alonso and Fundación Alicia Koplowitz.
Publisher Copyright:
© 2020 The Authors
PY - 2022/1
Y1 - 2022/1
N2 - Background: Questionnaires are the current hallmark for quantifying social functioning in human clinical research. In this study, we compared self- and proxy-rated (caregiver and researcher) assessments of social functioning in Schizophrenia (SZ) and Alzheimer's disease (AD) patients and evaluated if the discrepancy between the two assessments is mediated by disease-related factors such as symptom severity. Methods: We selected five items from the WHO Disability Assessment Schedule 2.0 (WHODAS) to assess social functioning in 53 AD and 61 SZ patients. Caregiver- and researcher-rated assessments of social functioning were used to calculate the discrepancies between self-rated and proxy-rated assessments. Furthermore, we used the number of communication events via smartphones to compare the questionnaire outcomes with an objective measure of social behaviour. Results: WHODAS results revealed that both AD (p < 0.001) and SZ (p < 0.004) patients significantly overestimate their social functioning relative to the assessment of their caregivers and/or researchers. This overestimation is mediated by the severity of cognitive impairments (MMSE; p = 0.019) in AD, and negative symptoms (PANSS; p = 0.028) in SZ. Subsequently, we showed that the proxy scores correlated more strongly with the smartphone communication events of the patient when compared to the patient-rated questionnaire scores (self; p = 0.076, caregiver; p < 0.001, researcher-rated; p = 0.046). Conclusion: Here we show that the observed overestimation of WHODAS social functioning scores in AD and SZ patients is partly driven by disease-related biases such as cognitive impairments and negative symptoms, respectively. Therefore, we postulate the development and implementation of objective measures of social functioning that may be less susceptible to such biases.
AB - Background: Questionnaires are the current hallmark for quantifying social functioning in human clinical research. In this study, we compared self- and proxy-rated (caregiver and researcher) assessments of social functioning in Schizophrenia (SZ) and Alzheimer's disease (AD) patients and evaluated if the discrepancy between the two assessments is mediated by disease-related factors such as symptom severity. Methods: We selected five items from the WHO Disability Assessment Schedule 2.0 (WHODAS) to assess social functioning in 53 AD and 61 SZ patients. Caregiver- and researcher-rated assessments of social functioning were used to calculate the discrepancies between self-rated and proxy-rated assessments. Furthermore, we used the number of communication events via smartphones to compare the questionnaire outcomes with an objective measure of social behaviour. Results: WHODAS results revealed that both AD (p < 0.001) and SZ (p < 0.004) patients significantly overestimate their social functioning relative to the assessment of their caregivers and/or researchers. This overestimation is mediated by the severity of cognitive impairments (MMSE; p = 0.019) in AD, and negative symptoms (PANSS; p = 0.028) in SZ. Subsequently, we showed that the proxy scores correlated more strongly with the smartphone communication events of the patient when compared to the patient-rated questionnaire scores (self; p = 0.076, caregiver; p < 0.001, researcher-rated; p = 0.046). Conclusion: Here we show that the observed overestimation of WHODAS social functioning scores in AD and SZ patients is partly driven by disease-related biases such as cognitive impairments and negative symptoms, respectively. Therefore, we postulate the development and implementation of objective measures of social functioning that may be less susceptible to such biases.
UR - http://www.scopus.com/inward/record.url?scp=85096369514&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2020.11.013
DO - 10.1016/j.jpsychires.2020.11.013
M3 - Article
C2 - 33221026
SN - 0022-3956
VL - 145
SP - 302
EP - 308
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
ER -